Life Science Webinars

  1. Biologics CDMO, Northway Biotech, expands to the US: Boston Facility Grand Opening 1/21/2021

    There is little doubt that biologics have transformed modern medicine in the treatment of many diseases and conditions - positively changing many people's futures. Biologics have revolutionized cancer treatment, reversed the course of immune related conditions, and offered new hope for patients with rare genetic conditions. As many biologics developers utilize CDMOs to augment their existing supply or use CDMOs for portions or all development and manufacturing needs – choosing the right outsourcing partner can be overwhelming. 

  2. Drug Repurposing Trends — A CDMO Perspective 1/20/2021

    Dr. Anil Kane, Executive Director, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, reviews drug repurposing trends and shares case studies to demonstrate how a CDMO plays a role in drug repurposing and supporting the pharmaceutical industry in taking drugs to market approval.

  3. Data Driven Strategies And Considerations For Scalable Purification Of Plasmid DNA For Use In Vaccine Manufacturing 1/12/2021

    Plasmid DNA (pDNA) presents unique manufacturing challenges. While research scale purification kits simplify small pDNA preparations, scalable manufacturing must leverage significant process understanding. This webinar presents scalable solutions for all downstream unit operations from harvest to bulk filtration.

  4. Unlocking The Potential Of mRNA Vaccines And Therapeutics: A Manufacturing Perspective 1/12/2021

    The therapeutic potential of mRNA has been studied for decades and this exciting modality could potentially disrupt the biological market, in particular vaccine and novel therapies. This webinar will highlight the potential of mRNA therapies and focus on the manufacturing process associated challenges, solutions and perspectives from synthesis to delivery.

  5. Benefits Of 5KL Bioreactor When Outsourcing Late-Phase Biologics Drug Substance Manufacturing 1/6/2021

    Watch this webinar today to discover how Thermo Fisher Scientific is addressing and overcoming two critical, current challenges in upstream bioprocessing.

  6. The Future Of Osmolality Testing Within Cell & Gene Therapy 1/4/2021

    Learn more about our latest osmometers designed for process development while seamlessly transferring into GMP environments with advanced data management features (21 CFR Part 11) in this presentation, hosted by Kendal Studd, Applications Scientist.

  7. Osmolality Testing: Providing Unique Process Control For Downstream Operations 12/27/2020

    Osmolality serves as a key orthogonal property in downstream processing. This webinar will demonstrate the value of osmolality testing as a key process parameter in buffer preparation, purification, and filtration operations.

  8. 21 CFR Part 11 Compliance And Osmolality As A Process Parameter 12/26/2020

    FDA warning letters due to incomplete data in the pharma and biotech industries can be prevented by ensuring the reliability of electronic records, a process known as Compliance with Data Integrity. 

  9. 8 Ways That Osmolality Testing Improves Cell And Gene Therapy Process Development And Manufacturing 12/26/2020

    Osmolality is a measure of solute concentration and an indication of the solution’s osmotic pressure (USP, EP). It provides the concentration of any solution and has several potential applications within cell and gene therapy development and manufacturing. Learn more about the role osmolality plays in viral vector stability.

  10. Approaching Digital Transformation: How Biopharm Should Prepare For Validation And Compliance 12/18/2020

    Data is critical for operations within the pharmaceutical and life sciences industries, whether it is for compliance, operational excellence, reporting or development. Data integrity enables convenience and trustworthiness in all types of data generated in several areas across the workflow. As more people, systems and tools consume data, it becomes increasingly valuable because it can be translated into action to improve quality and performance while reducing costs and time to market. However, with additional systems and users comes a risk that, if not managed correctly, can compromise the integrity of data.